Proteins and Peptides
8 August 2014
BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment of Lipoma7 August 2014
Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabete5 August 2014
Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile4 August 2014
Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint29 July 2014
ERYTECH Announces Enrollment of First Patient in Phase II Study of ERY-ASP in Pancreatic Cancer26 July 2014
Novo Nordisk receives positive opinion on Xultophy® (IDegLira) from the European regulatory authorities24 July 2014
PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis22 July 2014
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer22 July 2014
Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPHNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports